Clinical Trials Search at Vanderbilt-Ingram Cancer Center

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) based on conventional imaging, as compared to placebo plus ADT.

This clinical trial evaluates which methods of blood transfusion are best for patients undergoing kidney surgery. Allogenic (donor) blood transfusion has been shown to cause more side effects (with the lungs, immune system, and circulation, for example) as well as worse cancer outcomes. These concerns have encouraged methods to decrease allogenic blood transfusion. Blood transfusion is defined as a medical treatment that replaces blood that is lost during surgery and is causing changes in blood pressure or heart rate due to that loss. There are two sources of blood for transfusion, allogenic and autologous. Allogenic blood is blood that is provided from healthy blood donors. Autologous blood is provided from the patient for their own use. Techniques that can reduce the need for allogenic blood transfusion include acute normovolemic hemodilution and cell salvage, which use the patient's own blood (autologous) in transfusion. This study aims to reduce the number of units of allogenic (donated) blood that is transfused.

This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.

The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his / her physician would have already made the decision to treat patient with darolutamide per local standard practice.